TransCode Therapeutics (RNAZ) Stock Price

$8.08 0%

Sign up
to add to portfolio

AI Score

Hold
  • Alternative

    9
  • Fundamental

    1
  • Technical

    3

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on TransCode Therapeutics, AI stock picks, stock alerts and much more.

Sign up

RNAZ AI Stock Analysis

AI stock analysis for RNAZ is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like TransCode Therapeutics (RNAZ) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

TransCode Therapeutics (RNAZ) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of TransCode Therapeutics (RNAZ), currently trading at $8.08, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About RNAZ

LSE
  • TransCode Therapeutics, Inc.

  • Symbol

    RNAZ

  • Market

    NASDAQ

  • Industry

    Biotechnology

  • Market Cap

    5.6M

Similar Stocks

CPRX Catalyst Pharmaceuticals
CPRX
$21.62
2%
6
INO Inovio Pharmaceuticals
INO
$2.24
0.9%
2
MRNA Moderna
MRNA
$35.53
5.3%
4
AVXL Anavex Life Sciences
AVXL
$8.35
3.8%
6
BBIO BridgeBio Pharma
BBIO
$36.85
0.1%
6

RNAZ Alternative Data

Web Traffic

TransCode Therapeutics receives an estimated 1734 monthly visitors to transcodetherapeutics.com.

  • Web Traffic

    1734

  • Change from Previous Month

    1.1%

  • 3 Month Change

    10%

  • YoY Change

    10%

News Mentions

TransCode Therapeutics was mentioned 1 times in the news yesterday.

  • News Mentions

    1

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Reddit Mentions

TransCode Therapeutics has been mentioned an estimated 2 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    2

  • Daily Change

    0%

Twitter Followers

TransCode Therapeutics has 316 Twitter Followers on its main Twitter (also known as X) account, which is up by 1.6% over the last month.

  • Twitter Followers

    316

  • Daily Change

    0%

  • 1 Month Change

    1.6%

  • 3 Month Change

    0.3%

  • YoY Change

    0.3%

LinkedIn Followers

1,981 are following TransCode Therapeutics on LinkedIn, up by 1.9% over the last month.

  • LinkedIn Followers

    1981

  • Daily Change

    0%

  • 1 Month Change

    1.9%

  • 3 Month Change

    4.8%

Job Postings

TransCode Therapeutics currenly has an estimated 0 open job postings.

  • Job Postings

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

LinkedIn Employees

According to LinkedIn, TransCode Therapeutics has 11 employees.

  • LinkedIn Employees

    11

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

RNAZ Financials

RNAZ Key Metrics
  • Total Revenue

    $0

  • Net Income

    -$2.3M

  • Earnings per Share

    -$0.16

  • Free cash flow

    -$3.9M

  • EBITDA

    -$2.2M

  • EBITDA Ratio

    0

  • Total Assets

    $3.9M

RNAZ 2-year Revenue & Income
RNAZ 2-year Free Cash Flow

RNAZ Technicals

RNAZ SMA
RNAZ RSI

FAQ

What's the current price of TransCode Therapeutics (RNAZ) Stock?
The price of an TransCode Therapeutics (RNAZ) share is $8.08.

What's the market cap of TransCode Therapeutics?
The current market cap of TransCode Therapeutics is 5.6M.

Should I buy or sell RNAZ?
TransCode Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, TransCode Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.

Is TransCode Therapeutics a good investment?
The current analysis of TransCode Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in TransCode Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy TransCode Therapeutics (RNAZ) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for TransCode Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to TransCode Therapeutics (RNAZ) that investors often compare it to?
TransCode Therapeutics (RNAZ) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.

What is the forecast for TransCode Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast TransCode Therapeutics' stock price to be around $7.8 in 2026. Starting from the current price of $8.08, this represents a 3.4% change in price, indicating a neutral outlook for the stock.

How to buy TransCode Therapeutics (RNAZ) Stock?
TransCode Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy TransCode Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.